FDA Lambastes Payment Model and its Impact on U.S. ‘Anemic’ Biosimilar Market
July 20, 2018
Mari Serebrov
BioWorld
Axinn partner Stacie Ropka, PhD was quoted in the BioWorld article, "FDA Lambastes Payment Model and its Impact on U.S. 'Anemic' Biosimilar Market."
Click here to access the article.